Business
ZYUS Life Sciences Announces Grant of Stock Options and Deferred Share Units
ZYUS Life Sciences Announces Grant of Stock Options and Deferred Share Units Canada NewsW...
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"\n\n\nZYUS Life Sciences Announces Grant of Stock Options and Deferred Share Units\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\nSASKATOON, SK , Dec. 1, 2025 /CNW/ - ZYUS Life Sciences Corporation (the \"Company\") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management, today announced the issuance of equity-based incentives under its omnibus equity compensation plan (the \"Omnibus Plan\").\n\n\n\n\n\n\n\nGrant of Stock Options\nPursuant to the Company's Omnibus Plan, the Company granted stock options to purchase up to an aggregate of 2,463,694 common shares of the Company, which includes 700,000 options issued to members of the senior leadership team, being officers of the Company. The stock options were approved for grant on November 26, 2025, and priced on November 27, 2025, following the expiry of a trading blackout period. The options are exercisable at a price of $0.65 per share, being the closing price on November 27, 2025, and are exercisable for a period of five years and have various vesting schedules.\nGrant of Deferred Share Units \nPursuant to the Company's Omnibus Plan, the Company also granted Deferred Share Units (\"DSUs\") representing an aggregate of 295,482 common shares of the Company issued to members of the Board of Directors. The DSUs were issued in lieu of cash fees for board services covering the periods of Q3-Q4 2023, Q1-Q4 2024 and Q1-Q2 2025.\nThe DSUs were approved for grant on November 26, 2025, and the number of DSUs granted was based on $0.65 per share, which was the closing price of the Company's common shares on November 27, 2025.\nAbout ZYUS Life Sciences Corporation \nZYUS (TSXV: ZYUS) is a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management. Currently, ZYUS i...